Merus N.V. (MRUS)
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors.
The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease.
In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co.
Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication.
Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
|IPO Date||May 19, 2016|
Utrecht, Utrecht 3584 CM
|Phone||31 30 253 8800|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Sven Ante Lundberg||Chief Executive Officer, President, Principal Financial Officer and Executive Director|
|Peter B. Silverman J.D.||Executive Vice President, General Counsel, Chief Intellectual Property Officer and Head of Utrecht and US Legal|
|Hui Liu||Chief Business Officer, Executive Vice President and Head of Merus U.S.|
|Dr. Hennie Hoogenboom||Co-Founder and Scientific Advisor|
|Cornelis Adriaan de Kruif Ph.D.||Chief Technology Officer and Senior Vice President|
|Dr. Cecile A.W. Geuijen Ph.D.||Chief Scientific Officer|
|Jillian Connell||Vice President of Investor Relations and Corporate Communications|
|Alexander Berthold Hendrik Bakker Ph.D.||Chief Development Officer and Senior Vice President|
|Dr. Andrew Joe M.D.||Chief Medical Officer|
|Anne Van der Touw Noordzij||Company Secretary|
Latest SEC Filings
|Nov 8, 2021||8-K||Current report|
|Nov 8, 2021||424B5||Prospectus [Rule 424(b)(5)]|
|Nov 4, 2021||424B5||Prospectus [Rule 424(b)(5)]|
|Nov 2, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Oct 8, 2021||4||Statement of changes in beneficial ownership of securities|
|Aug 16, 2021||4||Statement of changes in beneficial ownership of securities|
|Aug 10, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Aug 5, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Aug 4, 2021||4||Statement of changes in beneficial ownership of securities|
|Jul 7, 2021||4||Statement of changes in beneficial ownership of securities|
|View All SEC Filings|